Dusigitumab

Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGLF2.[1] It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix.[2]

Dusigitumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetILGF2
Clinical data
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
KEGG
Chemical and physical data
FormulaC6372H9824N1700O2016S54
Molar mass151 kg/mol g·mol−1

References
  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Dusigitumab, American Medical Association.
  2. http://adisinsight.springer.com/drugs/800030209
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.